|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In some studies genetic variation in the renin-angiotensin-aldosterone system (RAAS) has been associated with hypertension and rapid progression of renal insufficiency to end-stage renal disease (ESRD).
|
12832734 |
2003 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of interaction of polymorphisms in the Renin-Angiotensin-System (RAS) with angiotensin converting enzyme (ACE) or angiotensin receptor (AGTR1) inhibitors (RAS inhibitors) is unknown, as is the role of such therapy in end stage renal disease (ESRD) patients.
|
15946912 |
2005 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With the realization that lowering blood pressure, including with renin-angiotensin system blockade, failed to reliably prevent end-stage kidney disease, studies now are analyzing longer-term effects of hypertension control on survival in chronic kidney disease.
|
28087008 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, this polymorphism may interact with other polymorphisms within the renin-angiotensin system, leading to high risk of ESRD.
|
16088846 |
2005 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans.
|
8989734 |
1996 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined an association of the three renin-angiotensin system (RAS) gene polymorphisms with renal disease and progression to ESRD in dialyzed patients.
|
16384824 |
2006 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of the renin-angiotensin system (RAS) have been implicated in the pathogenesis of nephropathy and end-stage renal disease (ESRD).
|
15012717 |
2003 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin system polymorphisms: a risk factor for progression to end-stage renal disease in vesicoureteral reflux patients.
|
19288324 |
2009 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite optimal therapy of diabetic nephropathy with agents blocking the renin-angiotensin-aldosterone system, the residual risk of nephropathy progression to end-stage renal disease (ESRD) remains high.
|
28520568 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin system gene polymorphisms: its impact on IgAN and its progression to end-stage renal failure among Chinese in Singapore.
|
15153745 |
2004 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that heterozygous substitutions at the AGT M235T and REN A/G(I8-83) loci correlate significantly with ESRD in a north Indian population.
|
25660845 |
2015 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite optimal management of diabetic kidney disease (DKD) with intensive glycemic control and administration of agents blocking the renin-angiotensinaldosterone- system, the residual risk for nephropathy progression to end-stage-renal-disease (ESRD) remains high.
|
29792136 |
2019 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy.
|
21163122 |
2010 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this pooled analysis of four prospective studies in CKD patients treated with drugs inhibiting the renin-angiotensin system, we compared the risk of all-cause mortality, fatal and non-fatal cardiovascular (CV) events and end-stage renal disease (ESRD) between patients with (n = 693) and without diabetes (n = 1481) stratified by proteinuria level (<0.15, 0.15-0.49, 0.5-1 and >1 g/day).
|
29509925 |
2018 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Weight loss, either induced by diet or bariatric surgery, and renin-angiotensin blockers are effective treatments to slow progression, but a significant proportion of cases will develop end-stage renal disease.
|
27414023 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease.
|
16105049 |
2005 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
|
29216260 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of genetic variations involved in renin-angiotensin-aldosterone system (RAAS) pathway genes have clinical or physiological impacts on pathogenesis of hypertension-induced ESRD in ADPKD.
|
25001132 |
2014 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presumed superiority of renin-angiotensin-aldosterone system (RAAS)-blocking agents over other antihypertensive agents in patients with diabetes to delay development of end-stage kidney disease (ESKD) has recently been challenged.
|
29106631 |
2018 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Animal studies show that the renin-angiotensin system contributes to hypertension, glomerulosclerosis and progressive chronic renal failure in renal disease.
|
7700001 |
1994 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, genes of the renin-angiotensin-aldosterone system are candidate genes for further understanding of the interindividual differences in the development and course of ESRD.
|
11422735 |
2001 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mid-regional pro-atrial natriuretic peptide (MR-proANP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), vasopressin (AVP) and copeptin (CT-proAVP), metanephrines and normetanephrines, renin and aldosterone, standard transthoracic echocardiography and diameter of vena cava inferior (VCID) were performed in 20 patients with end stage renal disease (CKD5D) before and after HD and were stratified in residual excretion (RE, less or more 0.5 l) and ultrafiltration rate (UF, less or more 2 l).
|
28558715 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients treated with renin-angiotensin system blockade or calcium channel blockers during follow-up had significantly later onset of ESRD by 4.3 years and 2.1 years, respectively.
|
22297678 |
2012 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin system is considered important in the genesis of hypertension and development of end-stage renal disease (ESRD) in autosomal dominant polycystic kidney disease (ADPKD).
|
10983692 |
2000 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings support the previous speculation that the renin-angiotensin system could be a local factor involved in the progression of chronic renal failure and consequent development of hypertension.
|
9533422 |
1998 |